Terminal modifications inhibit proteolytic degradation of an immunogenic MART-127-35 peptide: Implications for peptide vaccines

International Journal of Cancer

Volumn 83, Issue 3, 1999, Pages 326-334

  Brinckerhoff, Laurence H ^a   Kalashnikov, Vladimir V ^b   Thompson, Lee W ^a   Yamshchikov, Galina V ^a   Pierce, Richard A ^b   Galavotti, Holly S ^a   Engelhard, Victor H ^b   Slingluff Jr , Craig L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPITOPE; PEPTIDE;

ANTIGEN PRESENTING CELL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG STABILITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; MELANOMA; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE; ENDOPEPTIDASES; EPITOPES, T-LYMPHOCYTE; HUMANS; MELANOMA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032833799     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19991029)83:3<326::AID-IJC7>3.0.CO;2-X     Document Type: Article

References (21)

1. AICHELE, P., BRDUSCHA-RIEM, K., ZINKERNAGEL, R.M., HENGARTNER, H. and PIRCHER, H., T-cell priming versus T-cell tolerance induced by synthetic peptide. J. exp. Med., 182, 261-266 (1995).
2. AYYOUB, M., MONSARRAT, B., MAZARGUIL, H. and GAIRIN, J.E., Analysis of the degradation mechanisms of MHC class I-presented tumor antigenic peptides by high performance liquid chromatography/electrospray ionization mass spectrometry: application to the design of peptidase-resistant analogues. Rapid Commun. Mass Spectrom., 12, 557-564 (1998).
3. BODERKE, P., MERKLE, H.P., CULLANDER, C., PONEC, M. and BODDE, H., Localization of aminopeptidase activity in freshly excised human skin: direct visualization by confocal laser scanning microscopy. J. invest. Dermatol., 108, 83-86 (1997).
4. CHEN, Y., SIDNEY, J., SOUTHWOOD, S., COX, A.L., SAKAGUCHI, K., HENDERSON, R.A., APPELLA, E., HUNT, D.F., SETTE, A., and ENGELHARD, V.H., Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecules HLA-A2.1 with high affinity and in different conformations. J. Immunol., 252, 2874-2881 (1994).
5. COX, A.L., SKIPPER, J., CHEN, Y., HENDERSON, R., DARROW, T.L., SHABANOWITZ, J., ENGELHARD, V.H., HUNT, D.F. and SLINGLUFF, C.L. JR., Identification of a peptide recognized by five melanoma-specific human cytotoxic T-cell lines. Science, 264, 716-719 (1994).
6. EDE, N.J., ANG, K.H., JAMES, I.W. and BRAY, A.M., Incorporation of 2-hydroxy-4-methoxybenzyl protection during peptide synthesis via reductive alkylation on the solid phase. Tetrahedron Lett., 37, 9097-9100 (1996).
7. HENDERSON, R.A., MICHEL, H., SAKAGUCHI, K., SHABANOWITZ, J., APPELLA, E., HUNT, D.F. and ENGELHARD, V.H., HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science, 255, 1264-1266 (1992).
8. JAEGER, E., BERNHARD, H., ROMERO, P., RINGHOFFER, M., ARAND, M., KARBACH, J., ILSEMANN, C., HAGEDORN, M. and KNUTH A., Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implication for tumor vaccines with melanoma-associated antigens. Int. J. Cancer, 66, 162-169 (1996).
9. KATES, S.A., DE LA TORRE, B.G., ERITJA, R. and ALBERICIO, F., Solid-phase N-glycopeptide synthesis using allyl side-chain protected Fmoc-amino acids. Tetrahedron Lett., 35, 1033-1034 (1994).
10. KAWAKAMI, Y., ELIYAHU, S., SAKAGUCHI, K., ROBBINS, P.F., RIVOLTINI, L., YANNELLI, J.R., APPELLA, E., and ROSENBERG, S.A., Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. exp. Med., 180, 347-352, (1994).
11. LEE, V.H.L., Enzymatic barriers to peptide and protein absorption. CRC Crit. Rev. Therap. Drug Carrier Systems, 5, 69-97 (1988).
12. MAILLERE, B., MOURIER, G., HERVE, M. and MENEZ, A., Fine chemical modification at the N-and C-termini enhance peptide presentation in T cells by increasing the lifespan of both free and MHC-complexed peptides. Mol. Immunol., 32, 1377-1385 (1995).
13. MARBACH, P., BRINER, U., LEMAIRE, M., SCHWEITZER, A. and TERASAKI, T., From somatostatin to sandostatin: pharmacodynamics and pharmacokinetics. Digestion, 54 (Suppl 1), 9-13 (1993).
14. NAIR, S.K., BOCZKOWSKI, D., SNYDER, D. and GILBOA E., Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Europ. J. Immunol., 27, 589-597 (1997).
15. OFFER, J., QUIBELL, M. and JOHNSON, T., On-resin solid-phase synthesis of asparagine N-linked glycopeptides: use of N-(2-acetoxy-4-methoxybenzyl) (AcHmb) aspartyl amide-bond protection to prevent unwanted aspartimide formation. J. chem. Soc. [Perkin 1], 2, 175-182 (1996).
16. PARKHURST, M.R., SALGALLER, M.L., SOUTHWOOD, S., ROBBINS, P.F., SETTE, A., ROSENBERG, S.A. and KAWAKAMI, Y., Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at the HLA-A*0201-binding residues. J. Immunol., 157, 2539-2548 (1996).
17. POWELL, M.F., GREY, H., GAETA, F., SETTE, A. and COLON, S., Peptide stability in drug development: a comparison of peptide reactivity in different biologic media. J. pharm. Sci., 81, 731-735 (1992).
18. POWELL, M.F., STEWART, T., OTVOS, L., URGE, L., GAETA, F.C.A., SETTE, A., ARRHENIUS, T., THOMSON, D., SODA, K. and COLON, S.M., Peptide stability in drug development. II. Effects of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm. Res., 10, 1268-1273 (1993).
19. SKIPPER, J.C.A., KITTLESEN, D.J., HENDRICKSON, R.C., DEACON, D.D., HARTHUN, N.L., WAGNER, S.N., HUNT, D.F., ENGELHARD, V.H. and SLINGLUFF, C.L. JR., Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J. Immunol., 157, 5027-5033 (1996).
20. VALMORI, D., FONTENEAU, J.F., LIZANA, C.M., GERVOIS, N., LIENARD, D., RIMOLDI, D., JONGENEEL, V., JOTEREAU, F., CEROTTINI, J.C., and ROMERO, P., Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol., 160, 1750-1758, (1998).
21. WEISS, J.M., SLEEMAN, J., RENKL, A.C., DITTMAR, H., TERMEER, C.C., TAXIS, S., HOWELLS, N., HOFMANN, M., KOHLER, G., SCHOPF, E., PONTA, H., HERRLICH, P. and SIMON, J.C., An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function. J. Cell Biol., 137, 1137-1147 (1997).